UPDATE: Pfizer Achieves Primary Endpoint With Phase 3B Top-Line Results Of GENOTROPIN® In Very Young Children Born Small For Gestational Age
March 26, 2014 at 08:03 AM EDT
Pfizer Inc. (NYSE: PFE) announced today the top-line results from a Phase 3B study evaluating the 24-month efficacy of GENOTROPIN® ...
